Specifications tableSubject area*Breast cancer*More specific subject area*Diet supplementation with walnut*Type of data*Tables of modified genes and gene pathways*How data was acquired*Next-gen sequencing of mRNA from breast cancer tumors*\
Total RNA was extracted from biopsy or surgical specimens using RNeasy, Lipid Tissue kit ([Qiagen.com](http://Qiagen.com){#intref0010}). RNA sample quality was assessed on RNA Pico chips in using an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). One microgram of total RNA was used to construct RNA-Seq libraries using a TruSeq stranded total RNA library prep kit with RiboZero(H∖M∖R) ribosomal RNA reduction (Illumina Inc., San Diego, CA) according to the kit\'s instructions.\
Twenty RNA-Seq libraries were clustered on an Illumina cBot and sequenced on a HiSeq 1500 platform, in a 2 x 50 base paired end design yielding a minimum of 50 million reads per sample.\
Reads were trimmed using Trimmomatic v 0.36 [@bib2] to remove low-quality base calls and adapter sequences, and then aligned to the human reference genome GRCh38 using HISAT v2.1.0 [@bib3]. Resulting bam files were sorted and indexed with SamTools v1.3.1 [@bib3], [@bib4], and PCR and optical duplicate reads marked using Picard tools v2.6.0. The numbers of reads mapping to each gene for each sample were counted using the R/Bioconductor package GenomicAlignments, v1.12.2 [@bib5] and the Ensembl gene database for GRCh38, build 84 [@bib6]. Differential gene expression was computed using DESeq2 version 1.10.0 [@bib7], with a statistical model comparing the ratio of expression between surgery and biopsy specimens for the walnut-consuming group to the ratio of expression between surgery and biopsy specimens for the control group.Data formatRaw expression reads were analyzed by Ingenuity Pathway to identify changed gene expressions in the tumor by walnut consumption.Experimental factorsWomen with breast cancer in the walnut group consumed 2 ounces of walnuts per day for 2--3 weeks, the control group did not consume walnut.Experimental featuresThe data were obtained in a non-placebo, two-arm, clinical trial. Women with breast lumps large enough for research and pathology biopsies were recruited and randomized to walnut consuming or control groups. Immediately after biopsy collection, women in the walnut group began to consume two ounces of walnuts per day until follow-up surgery, the control group did not consume walnut. Pathology confirmed that lumps were breast cancer in all women who remained in the trial. At surgery, about two weeks after biopsy, additional specimens were taken from the breast cancers. Changes in gene expression in the surgical specimen compared to baseline biopsy were determined in each individual woman in walnut-consuming (n = 5) and control (n = 5) groups. RNA-Seq was performed. Resulting expression data were analyzed by Ingenuity pathway analyses.Data source locationHuntington, West VirginiaData accessibilityFiles containing the raw reads, along with a shell script describing the complete data analysis pipeline, were deposited to the Gene Expression Omnibus (GEO) at the National Center for Biotechnology Information (NCBI) and can be obtained via accession number [GSE111073](ncbi-geo:GSE111073){#intref0015}. <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111073>Related research articleHardman WE, Primerano DA, Legenza MA, Morgan J, Fan J, Denvir J. Dietary walnut altered gene expressions related to tumor growth, survival, and metastasis in breast cancer patients: a pilot clinical trial. Nutr Research 2019; In Press. <https://doi.org/10.1016/j.nutres.2019.03.004>**Value of the data This data can be of value to those who:**•desire to further investigate synergism between diet and cancer therapy•desire to understand why some cancers responded to the dietary intervention and some may not•desire to discover beneficial combinations of dietary components and/or standard cancer therapies by understanding the genes that are influenced

1. Data {#sec1}
=======

The data in [Table 1](#tbl1){ref-type="table"} present the known genes in which the log ratio of \[(gene expressions in the breast tumor at surgery) divided by (the expression of that gene in the initial biopsy)\] in the subjects who consumed walnut divided by the \[(gene expressions in the breast tumor at surgery) divided by (the expression of that gene in the initial biopsy)\] of that gene in the control subjects were significant. Thus, this data shows the genes in which mRNA expression was significantly changed by consumption of walnut compared to control and the direction of that change (increased or decreased).Table 1All mapped loci. ^©^ 2000--2018 QIAGEN. All rights reserved.Table 1Expr log ratioExpr false discovery rate (q-value)IDFlagsSymbolEntrez gene nameLocationType(s)Drug(s)28.235.54E-03ENSG00000255277ABCC6P2ATP binding cassette subfamily C member 6 pseudogene 2Otherother27.995.54E-03ENSG00000144827ABHD10abhydrolase domain containing 10Cytoplasmenzyme−26.168.26E-03ENSG00000165660ABRAXAS2abraxas 2, BRISC complex subunitNucleusother−27.925.54E-03ENSG00000226359ACTG1P24actin gamma 1 pseudogene 24Otherother−23.185.24E-06ENSG00000168594ADAM29ADAM metallopeptidase domain 29Plasma Membranepeptidase−26.197.91E-03ENSG00000274376ADAMTS7P1ADAMTS7 pseudogene 1Otherother−16.277.38E-02ENSG00000065457ADAT1adenosine deaminase, tRNA specific 1Otherenzyme26.857.20E-03ENSG00000204818ADGRF5P2adhesion G protein-coupled receptor F5 pseudogene 2Otherother25.988.69E-03ENSG00000156920ADGRG4adhesion G protein-coupled receptor G4Plasma MembraneG-protein coupled receptor−28.075.54E-03ENSG00000243289AGAP13PArfGAP with GTPase domain, ankyrin repeat and PH domain 13, pseudogeneOtherother30.004.30E-03ENSG00000196581AJAP1adherens junctions associated protein 1Plasma Membraneother26.138.21E-03ENSG00000140057AK7adenylate kinase 7Cytoplasmkinase−29.864.30E-03ENSG00000108602ALDH3A1aldehyde dehydrogenase 3 family member A1Cytoplasmenzyme−26.697.65E-03ENSG00000163046ANKRD30BLankyrin repeat domain 30B likeOtherother−26.367.91E-03ENSG00000224309ANKRD30BP2ankyrin repeat domain 30B pseudogene 2Otherother29.964.30E-03ENSG00000184945AQP12A/AQP12Baquaporin 12ACytoplasmtransporter30.004.30E-03ENSG00000198576ARCactivity regulated cytoskeleton associated proteinCytoplasmother25.988.69E-03ENSG00000127249ATP13A4ATPase 13A4Cytoplasmtransporter27.735.66E-03ENSG00000228847ATP5G2P4ATP synthase, H+ transporting, mitochondrial Fo complex subunit C2 (subunit 9) pseudogene 4Otherother20.559.40E-02ENSG00000230223ATXN8OSATXN8 opposite strand (non-protein coding)Otherother27.057.01E-03ENSG00000148090AUHAU RNA binding methylglutaconyl-CoA hydrataseCytoplasmenzyme−29.794.30E-03ENSG00000198049AVPR1Barginine vasopressin receptor 1BPlasma MembraneG-protein coupled receptorAVP, lypressin−29.844.30E-03ENSG00000187172BAGE2BAGE family member 2Otherother−25.631.10E-02ENSG00000100739BDKRB1bradykinin receptor B1Plasma MembraneG-protein coupled receptor−27.715.66E-03ENSG00000224809BEND3P2BEN domain containing 3 pseudogene 2Otherother25.699.93E-03ENSG00000204960BLACEB-cell acute lymphoblastic leukemia expressedOtherother−29.714.30E-03ENSG00000186222BLOC1S4biogenesis of lysosomal organelles complex 1 subunit 4Cytoplasmother−29.924.30E-03ENSG00000125845BMP2bone morphogenetic protein 2Extracellular Spacegrowth factor−26.197.91E-03ENSG00000198183BPIFA1BPI fold containing family A member 1Extracellular Spaceother28.235.54E-03ENSG00000224775BRAFP1BRAF pseudogene 1Otherother−29.844.30E-03ENSG00000226913BSN-AS2BSN antisense RNA 2 (head to head)Otherother−30.004.30E-03ENSG00000137656BUD13BUD13 homologNucleusother−26.197.91E-03ENSG00000173237C11orf86chromosome 11 open reading frame 86Otherother−28.545.52E-03ENSG00000157330C1orf158chromosome 1 open reading frame 158Otherother−25.719.87E-03ENSG00000188511C22orf34chromosome 22 open reading frame 34Otherother−26.197.91E-03ENSG00000173557C2orf70chromosome 2 open reading frame 70Nucleusother−30.004.30E-03ENSG00000237787C3orf79chromosome 3 open reading frame 79Otherother26.467.91E-03ENSG00000082213C5orf22chromosome 5 open reading frame 22Otherother2.656.09E-02ENSG00000256462CALML3calmodulin like 3Cytoplasmother−26.197.91E-03ENSG00000141668CBLN2cerebellin 2 precursorExtracellular Spaceother−26.497.91E-03ENSG00000183287CCBE1collagen and calcium binding EGF domains 1Extracellular Spaceother−28.545.52E-03ENSG00000100147CCDC134coiled-coil domain containing 134Otherother28.235.54E-03ENSG00000163081CCDC140coiled-coil domain containing 140Otherother−28.495.52E-03ENSG00000248712CCDC153coiled-coil domain containing 153Otherother−28.005.54E-03ENSG00000276409CCL14C--C motif chemokine ligand 14Extracellular Spacecytokine−29.964.30E-03ENSG00000133101CCNA1cyclin A1Nucleusother−28.805.52E-03ENSG00000238241CCR12PC--C motif chemokine receptor 12, pseudogeneOtherother−26.367.91E-03ENSG00000204933CD177P1CD177 molecule pseudogene 1Otherother−27.066.99E-03ENSG00000158477CD1ACD1a moleculePlasma Membraneother−26.697.65E-03ENSG00000184661CDCA2cell division cycle associated 2Nucleusother−27.066.99E-03ENSG00000145526CDH18cadherin 18Plasma Membraneother17.962.14E-03ENSG00000113100CDH9cadherin 9Plasma Membraneother26.767.20E-03ENSG00000170312CDK1cyclin dependent kinase 1Nucleuskinasedinaciclib, AG 024322, AZD5438, milciclib, SB-1317, roniciclib, alvocidib−25.719.87E-03ENSG00000230666CEACAM22Pcarcinoembryonic antigen related cell adhesion molecule 22, pseudogeneOtherother−26.197.91E-03ENSG00000273203CECR7cat eye syndrome chromosome region, candidate 7 (non-protein coding)Otherother19.246.08E-02ENSG00000267448CELF5CUGBP Elav-like family member 5Nucleusother25.988.69E-03ENSG00000272514CFAP206cilia and flagella associated protein 206Cytoplasmother−27.027.01E-03ENSG00000258469CHMP4BP1charged multivesicular body protein 4B pseudogene 1Otherother−14.777.91E-03ENSG00000181072CHRM2cholinergic receptor muscarinic 2Plasma MembraneG-protein coupled receptorfesoterodine, ABT-089, dimetindene, protoveratrine derivative, aclidinium, dextromethorphan/quinidine, umeclidinium, glycopyrrolate/indacaterol, umeclidinium/vilanterol, olodaterol/tiotropium, indacaterol/tiotropium, formoterol/glycopyrrolate, donepezil/solifenacin, glycopyrrolate/indacaterol/mometasone furoate, atropine/edrophonium, cyclopentolate/phenylephrine, albuterol/ipratropium, trihexyphenidyl, carbamylcholine, diphenhydramine/ibuprofen, methacholine, dexamethasone/olanzapine, diphenhydramine, doxepin, quinidine, procyclidine, trospium, rocuronium, homatropine, dicyclomine, methantheline, orphenadrine, fluoxetine/olanzapine, doxacurium, aspirin/caffeine/orphenadrine, propantheline, tridihexethyl, biperiden, anisotropine methylbromide, glycopyrrolate, atropine/hyoscyamine/phenobarbital/scopolamine, atropine/diphenoxylate, pipecuronium, flavoxate, chlorpheniramine/methscopolamine/phenylephrine, mepenzolic acid, homatropine methylbromide, hydroxyamphetamine/tropicamide, cisatracurium, hyoscyamine/phenobarbital, triflupromazine, bethanechol, olanzapine, oxybutynin, tropicamide, solifenacin, cyclopentolate, gallamine triethiodide, tolterodine, cevimeline, acetylcholine, ipratropium, atropine, pilocarpine, benztropine, hyoscyamine, arecoline, scopolamine, N-methylscopolamine, tiotropium, carbinoxamine, buclizine, benzquinamide, diphenhydramine/phenylephrine, brompheniramine−27.925.54E-03ENSG00000172322CLEC12AC-type lectin domain family 12 member APlasma Membraneother−28.075.54E-03ENSG00000111729CLEC4AC-type lectin domain family 4 member APlasma Membranetransmembrane receptor−30.004.30E-03ENSG00000104938CLEC4MC-type lectin domain family 4 member MPlasma Membraneother−25.719.87E-03ENSG00000205057CLLU1OSchronic lymphocytic leukemia up-regulated 1 opposite strandOtherother26.507.91E-03ENSG00000155052CNTNAP5contactin associated protein like 5Otherother−27.925.54E-03ENSG00000231595COX10COX10, heme A:farnesyltransferase cytochrome c oxidase assembly factorCytoplasmenzyme−27.425.67E-03ENSG00000258981COX5AP2cytochrome c oxidase subunit 5A pseudogene 2Otherother29.364.56E-03ENSG00000117322CR2complement C3d receptor 2Plasma Membranetransmembrane receptor−16.355.28E-02ENSG00000276076CRYAA/LOC102724652crystallin alpha ACytoplasmother28.235.54E-03ENSG00000135222CSN2casein betaExtracellular Spacekinase−29.344.45E-03ENSG00000170367CST5cystatin DCytoplasmother−29.444.37E-03ENSG00000228836CT45A10/CT45A5cancer/testis antigen family 45 member A5Otherother−26.697.65E-03ENSG00000235857CTBP2P1C-terminal binding protein 2 pseudogene 1Otherother−26.367.91E-03ENSG00000234993CUBNP2cubilin pseudogene 2Otherother−25.719.87E-03ENSG00000120280CXorf21chromosome X open reading frame 21Otherenzyme−26.197.91E-03ENSG00000183035CYLC1cylicin 1Cytoplasmother27.735.66E-03ENSG00000155833CYLC2cylicin 2Otherother−26.197.91E-03ENSG00000036530CYP46A1cytochrome P450 family 46 subfamily A member 1Cytoplasmenzyme−27.435.90E-03ENSG00000173406DAB1DAB1, reelin adaptor proteinCytoplasmother−26.367.91E-03ENSG00000179284DAND5DAN domain BMP antagonist family member 5Extracellular Spaceother−26.197.91E-03ENSG00000236709DAPK1-IT1DAPK1 intronic transcript 1Otherother30.004.30E-03ENSG00000152670DDX4DEAD-box helicase 4Nucleusenzyme27.246.68E-03ENSG00000164822DEFA6defensin alpha 6Extracellular Spaceother−29.774.30E-03ENSG00000205883DEFB135defensin beta 135Otherother26.477.91E-03ENSG00000058866DGKGdiacylglycerol kinase gammaCytoplasmkinase−26.367.91E-03ENSG00000104808DHDHdihydrodiol dehydrogenaseOtherenzyme−17.706.24E-02ENSG00000187908DMBT1deleted in malignant brain tumors 1Plasma Membranetransmembrane receptor−26.197.91E-03ENSG00000157851DPYSL5dihydropyrimidinase like 5Cytoplasmenzyme−25.719.87E-03ENSG00000125821DTD1D-tyrosyl-tRNA deacylase 1Cytoplasmenzyme25.988.69E-03ENSG00000198842DUSP27dual specificity phosphatase 27, atypicalOtherphosphatase−30.004.30E-03ENSG00000229758DYNLT3P2dynein light chain Tctex-type 3 pseudogene 2Otherother−22.513.61E-02ENSG00000104823ECH1enoyl-CoA hydratase 1Cytoplasmenzyme−28.075.54E-03ENSG00000268222EEF1A1P7eukaryotic translation elongation factor 1 alpha 1 pseudogene 7Otherother−28.805.52E-03ENSG00000235549EIF1P2eukaryotic translation initiation factor 1 pseudogene 2Otherother−25.719.87E-03ENSG00000227295ELL2P1elongation factor for RNA polymerase II 2 pseudogene 1Otherother−25.631.10E-02ENSG00000144488ESPNLespin likeExtracellular Spaceother−28.075.54E-03ENSG00000253831ETV3LETS variant 3 likeOtherother28.195.52E-03ENSG00000231882F10-AS1F10 antisense RNA 1Otherother−26.197.91E-03ENSG00000226766FABP7P1fatty acid binding protein 7 pseudogene 1Otherother−26.967.09E-03ENSG00000183508FAM46Cfamily with sequence similarity 46 member CExtracellular Spaceother30.004.30E-03ENSG00000174678FAM47DPfamily with sequence similarity 47 member D, pseudogeneOtherother−27.406.75E-03ENSG00000197872FAM49Afamily with sequence similarity 49 member AOtherother26.507.91E-03ENSG00000253488FAM60DPfamily with sequence similarity 60, member A pseudogeneOtherother26.477.91E-03ENSG00000224710DFAM90A26 (includes others)family with sequence similarity 90, member A26, pseudogeneOtherother26.477.91E-03ENSG00000231656DFAM90A26 (includes others)family with sequence similarity 90, member A26, pseudogeneOtherother26.477.91E-03ENSG00000237122DFAM90A26 (includes others)family with sequence similarity 90, member A26, pseudogeneOtherother−22.534.68E-02ENSG00000231060FARSBP1phenylalanyl-tRNA synthetase beta subunit pseudogene 1Otherother29.244.62E-03ENSG00000132185FCRLAFc receptor like APlasma Membraneother19.895.10E-02ENSG00000181171FER1L6-AS1FER1L6 antisense RNA 1Otherother30.004.30E-03ENSG00000146618FERD3LFer3 like bHLH transcription factorNucleustranscription regulator28.565.52E-03ENSG00000106692FKTNfukutinExtracellular Spaceother−25.719.87E-03ENSG00000257800FNBP1P1formin binding protein 1 pseudogene 1Otherother26.477.91E-03ENSG00000086205FOLH1folate hydrolase 1Plasma Membranepeptidasecapromab pendetide−6.357.87E-02ENSG00000110195FOLR1folate receptor 1Plasma Membranetransporterfarletuzumab−26.967.09E-03ENSG00000258421FXNP1frataxin pseudogene 1Otherother27.735.66E-03ENSG00000177736FXNP2frataxin pseuodgene 2Otherother26.138.21E-03ENSG00000136750GAD2glutamate decarboxylase 2Cytoplasmenzymevalproic acid26.507.91E-03ENSG00000257594GALNT4polypeptide N-acetylgalactosaminyltransferase 4Cytoplasmenzyme25.988.69E-03ENSG00000109534GAR1GAR1 ribonucleoproteinNucleusother30.004.30E-03ENSG00000228376GAS2L1P2growth arrest specific 2 like 1 pseudogene 2Otherother−25.631.10E-02ENSG00000272695GAS6-AS2GAS6 antisense RNA 2 (head to head)Otherother26.857.20E-03ENSG00000168546GFRA2GDNF family receptor alpha 2Plasma Membranetransmembrane receptor−26.197.91E-03ENSG00000125861GFRA4GDNF family receptor alpha 4Plasma Membranetransmembrane receptor−29.724.37E-03ENSG00000197421GGT3Pgamma-glutamyltransferase 3 pseudogeneExtracellular Spaceother−28.545.52E-03ENSG00000223893GNL2P1G protein nucleolar 2 pseudogene 1Otherother−27.066.99E-03ENSG00000111711GOLT1Bgolgi transport 1BCytoplasmother−27.027.01E-03ENSG00000235984GPC5-AS1GPC5 antisense RNA 1Otherother28.585.52E-03ENSG00000232885GPC5-AS2GPC5 antisense RNA 2Otherother−26.367.91E-03ENSG00000182771GRID1glutamate ionotropic receptor delta type subunit 1Plasma Membraneion channel27.436.04E-03ENSG00000140307GTF2A2general transcription factor IIA subunit 2Nucleustranscription regulator−26.197.91E-03ENSG00000153767GTF2E1general transcription factor IIE subunit 1Nucleustranscription regulator−29.444.45E-03ENSG00000237099GYG1P2glycogenin 1 pseudogene 2Otherother21.027.22E-02ENSG00000145649GZMAgranzyme ACytoplasmpeptidase28.145.52E-03ENSG00000270604HCG17HLA complex group 17 (non-protein coding)Otherother−30.004.30E-03ENSG00000164588HCN1hyperpolarization activated cyclic nucleotide gated potassium channel 1Plasma Membraneion channel26.477.91E-03ENSG00000281831HCP5BHLA complex P5B (non-protein coding)Otherother−28.325.52E-03ENSG00000113924HGDhomogentisate 1,2-dioxygenaseCytoplasmenzyme28.235.52E-03ENSG00000273703HIST1H2BMhistone cluster 1H2B family member mNucleusother−29.722.14E-03ENSG00000274641HIST1H2BOhistone cluster 1H2B family member oNucleusother−30.004.30E-03ENSG00000224557HLA-DPB2major histocompatibility complex, class II, DP beta 2 (pseudogene)Otherother−30.004.30E-03ENSG00000232629HLA-DQB2major histocompatibility complex, class II, DQ beta 2Plasma Membranetransmembrane receptor28.155.54E-03ENSG00000220557HMGB1P13high mobility group box 1 pseudogene 13Otherother28.155.54E-03ENSG00000253516HMGB1P41high mobility group box 1 pseudogene 41Otherother−28.075.54E-03ENSG00000237285HNRNPA1P2heterogeneous nuclear ribonucleoprotein A1 pseudogene 2Otherother29.414.37E-03ENSG00000249271HNRNPA1P44heterogeneous nuclear ribonucleoprotein A1 pseudogene 44Otherother−26.807.20E-03ENSG00000120075HOXB5homeobox B5Nucleustranscription regulator−29.824.30E-03ENSG00000123407HOXC12homeobox C12Nucleustranscription regulator29.244.62E-03ENSG00000223855HRAT92heart tissue-associated transcript 92Otherother−26.197.91E-03ENSG00000248159HSPA8P11heat shock protein family A (Hsp70) member 8 pseudogene 11Otherother26.138.21E-03ENSG00000250356HSPE1P23heat shock protein family E (Hsp10) member 1 pseudogene 23Otherother25.699.93E-03ENSG00000232015HSPE1P25heat shock protein family E (Hsp10) member 1 pseudogene 25Otherother−27.925.54E-03ENSG00000148680HTR75-hydroxytryptamine receptor 7Plasma MembraneG-protein coupled receptoriloperidone, asenapine, sultopride, lurasidone, vortioxetine, brexpiprazole, eletriptan, almotriptan, amoxapine, fenfluramine, methysergide, ergotamine30.004.30E-03ENSG00000121351IAPPislet amyloid polypeptideExtracellular Spaceother−29.814.30E-03ENSG00000137965IFI44interferon induced protein 44Cytoplasmother−26.197.91E-03ENSG00000272311IFNL4P1interferon lambda 4 pseudogene 1Otherother−30.004.30E-03ENSG00000163395IGFN1immunoglobulin-like and fibronectin type III domain containing 1Nucleusother26.138.21E-03ENSG00000239855IGKV1-6immunoglobulin kappa variable 1-6Otherother−29.754.30E-03ENSG00000253823IGLV1-62immunoglobulin lambda variable 1--62 (pseudogene)Otherother25.988.69E-03ENSG00000253889IGLVI-38immunoglobulin lambda variable (I)-38 (pseudogene)Otherother−26.367.91E-03ENSG00000196083IL1RAPinterleukin 1 receptor accessory proteinPlasma Membranetransmembrane receptorCAN04−25.719.87E-03ENSG00000162594IL23Rinterleukin 23 receptorPlasma Membranetransmembrane receptor28.235.54E-03ENSG00000217539IQCB2PIQ motif containing B2 pseudogeneOtherother25.988.69E-03ENSG00000255679JRKL-AS1JRKL antisense RNA 1Otherother−15.268.56E-03ENSG00000242370KCNAB1-AS1KCNAB1 antisense RNA 1Otherother27.585.67E-03ENSG00000280650KCNIP4-IT1KCNIP4 intronic transcript 1Otherother−15.905.44E-03ENSG00000162989KCNJ3potassium voltage-gated channel subfamily J member 3Plasma Membraneion channel−27.925.54E-03ENSG00000257069KCNK4-TEX40KCNK4-TEX40 readthroughOtherother−25.631.10E-02ENSG00000143603KCNN3potassium calcium-activated channel subfamily N member 3Plasma Membraneion channel−22.963.92E-02ENSG00000150361KLHL1kelch like family member 1Cytoplasmother27.016.99E-03ENSG00000250221KRT8P32keratin 8 pseudogene 32Otherother27.585.67E-03ENSG00000198841KTI12KTI12 chromatin associated homologOtherother−27.027.01E-03ENSG00000217783LDHAL6FPlactate dehydrogenase A like 6F, pseudogeneOtherother28.325.52E-03ENSG00000179676LINC00305long intergenic non-protein coding RNA 305Otherother19.431.87E-02ENSG00000226250LINC00408long intergenic non-protein coding RNA 408Otherother−26.977.01E-03ENSG00000236384LINC00479long intergenic non-protein coding RNA 479Plasma Membraneother−25.719.87E-03ENSG00000251533LINC00605long intergenic non-protein coding RNA 605Otherother25.988.69E-03ENSG00000233746LINC00656long intergenic non-protein coding RNA 656Otherother−27.925.54E-03ENSG00000229404LINC00858long intergenic non-protein coding RNA 858Otherother−14.311.94E-02ENSG00000214145LINC00887long intergenic non-protein coding RNA 887Otherother−26.197.91E-03ENSG00000259361LINC00927long intergenic non-protein coding RNA 927Otherother−26.367.91E-03ENSG00000230174LINC01149long intergenic non-protein coding RNA 1149Otherother−26.367.91E-03ENSG00000274827LINC01297Otherother−26.197.91E-03ENSG00000244578LINC01391long intergenic non-protein coding RNA 1391Otherother−30.004.30E-03ENSG00000249306LINC01411long intergenic non-protein coding RNA 1411Otherother26.477.91E-03ENSG00000254211LINC01485long intergenic non-protein coding RNA 1485Otherother−27.435.67E-03ENSG00000231422LINC01516long intergenic non-protein coding RNA 1516Otherother27.585.67E-03ENSG00000262468LINC01569long intergenic non-protein coding RNA 1569Otherother−27.735.54E-03ENSG00000227115LINC01630long intergenic non-protein coding RNA 1630Otherother−26.367.91E-03ENSG00000230768LINC01676long intergenic non-protein coding RNA 1676Otherother30.004.30E-03ENSG00000227181LINC01688long intergenic non-protein coding RNA 1688Otherother−28.075.54E-03ENSG00000232046LINC01798long intergenic non-protein coding RNA 1798Otherother−30.001.44E-03ENSG00000223466LINC01825Otherother−28.075.54E-03ENSG00000264345LINC01894Otherother−25.631.10E-02ENSG00000254299LINC01944Otherother27.865.54E-03ENSG00000251085LINC01969long intergenic non-protein coding RNA 1969Otherother−29.984.30E-03ENSG00000273033LINC02035long intergenic non-protein coding RNA 2035Otherother−29.924.30E-03ENSG00000229155LINC02038Otherother−29.974.30E-03ENSG00000241696LINC02053long intergenic non-protein coding RNA 2053Otherother−30.004.30E-03ENSG00000260896LINC02170long intergenic non-protein coding RNA 2170Otherother29.904.30E-03ENSG00000260792LINC02280long intergenic non-protein coding RNA 2280Otherother−28.545.52E-03ENSG00000257056LINC02282long intergenic non-protein coding RNA 2282Otherother29.964.30E-03ENSG00000258859LINC02296Otherother28.235.52E-03ENSG00000258998LINC02302long intergenic non-protein coding RNA 2302Otherother−18.026.20E-02ENSG00000255002LINC02324long intergenic non-protein coding RNA 2324Otherother29.604.37E-03ENSG00000248338LINC02472Otherother27.735.66E-03ENSG00000249362LINC02488Otherother−27.875.54E-03ENSG00000168216LMBRD1LMBR1 domain containing 1Cytoplasmtransporter−25.631.10E-02ENSG00000257711LOC100505978uncharacterized LOC100505978Otherother28.235.52E-03ENSG00000228877LOC100506532uncharacterized LOC100506532Otherother−28.525.52E-03ENSG00000243491LOC100996549uncharacterized LOC100996549Otherother30.004.30E-03ENSG00000225768LOC101927523uncharacterized LOC101927523Otherother−30.004.30E-03ENSG00000236039LOC101927630uncharacterized LOC101927630Otherother−26.197.91E-03ENSG00000249419LOC101928052uncharacterized LOC101928052Otherother−26.367.91E-03ENSG00000264464LOC101928144uncharacterized LOC101928144Otherother−29.634.45E-03ENSG00000253447LOC102724551uncharacterized LOC102724551Otherother−26.367.91E-03ENSG00000259170LOC104613533uncharacterized LOC104613533Otherother−28.495.52E-03ENSG00000257023LOC105369691uncharacterized LOC105369691Otherother20.588.43E-02ENSG00000258167LOC105369736uncharacterized LOC105369736Otherother−29.774.30E-03ENSG00000269720LOC105372343Otherother30.004.30E-03ENSG00000273877LOC105373373Otherother−27.027.01E-03ENSG00000251652LOC105374344Otherother−26.197.91E-03ENSG00000275846LOC105374989uncharacterized LOC105374989Otherother29.934.30E-03ENSG00000253699LOC105375623uncharacterized LOC105375623Otherother−17.611.59E-03ENSG00000253477LOC105375690uncharacterized LOC105375690Otherother27.815.54E-03ENSG00000267559LOC105376108Otherother−27.326.26E-03ENSG00000254670LOC105376557uncharacterized LOC105376557Otherother−26.367.91E-03ENSG00000226969LOC105378591Otherother29.384.45E-03ENSG00000251616LOC105379178uncharacterized LOC105379178Otherother−26.367.91E-03ENSG00000259697LOC107984784uncharacterized LOC107984784Otherother−26.367.91E-03ENSG00000255545LOC283177uncharacterized LOC283177Otherother30.004.30E-03ENSG00000250658LOC339975uncharacterized LOC339975Otherother−29.972.89E-04ENSG00000243440LOC388813uncharacterized protein ENSP00000383407-likeOtherother−28.545.52E-03ENSG00000263711LOC400655uncharacterized LOC400655Otherother28.195.52E-03ENSG00000277654LOC440311NOP53 ribosome biogenesis factor pseudogeneOtherother28.235.54E-03ENSG00000259663LOC642366uncharacterized LOC642366Otherother26.138.21E-03ENSG00000278849LOC642929general transcription factor II, i pseudogeneOtherother−29.624.37E-03ENSG00000230563LOC643406uncharacterized LOC643406Otherother−26.197.91E-03ENSG00000241014LOC653160uncharacterized LOC653160Otherother30.004.30E-03ENSG00000204913LRRC3Cleucine rich repeat containing 3COtherother−30.004.30E-03ENSG00000141639MAPK4mitogen-activated protein kinase 4Cytoplasmkinase−28.545.52E-03ENSG000001445834-Marmembrane associated ring--CH--type finger 4Cytoplasmenzyme−29.974.30E-03ENSG00000248109MARCOLOtherother−26.197.91E-03ENSG00000139915MDGA2MAM domain containing glycosylphosphatidylinositol anchor 2Otherother−25.719.87E-03ENSG00000130772MED18mediator complex subunit 18Nucleusother−29.824.30E-03ENSG00000229623METTL21AP1methyltransferase like 21A pseudogene 1Otherother−26.197.91E-03ENSG00000250878METTL21EPmethyltransferase like 21E, pseudogeneOtherother26.138.21E-03ENSG00000100060MFNGMFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferaseCytoplasmenzyme30.004.30E-03ENSG00000116691MIIPmigration and invasion inhibitory proteinOtherother−25.719.87E-03ENSG00000207779mir-15microRNA 15aCytoplasmmicroRNA−28.335.52E-03ENSG00000265322Dmir-3118microRNA 3118-3OthermicroRNA−28.335.52E-03ENSG00000265793Dmir-3118microRNA 3118-3OthermicroRNA28.155.54E-03ENSG00000266299Dmir-3118microRNA 3118-3OthermicroRNA27.016.99E-03ENSG00000265932mir-3146microRNA 3146CytoplasmmicroRNA26.857.20E-03ENSG00000212014mir-506microRNA 508CytoplasmmicroRNA−28.425.52E-03ENSG00000215973mir-933microRNA 933CytoplasmmicroRNA27.016.99E-03ENSG00000264049MIR4737microRNA 4737CytoplasmmicroRNA−28.075.54E-03ENSG00000278108MIR6757microRNA 6757OthermicroRNA−26.367.91E-03ENSG00000224430MKRN5Pmakorin ring finger protein 5, pseudogeneOtherother−29.524.37E-03ENSG00000230500MKX-AS1MKX antisense RNA 1Otherother−27.066.99E-03ENSG00000082515MRPL22mitochondrial ribosomal protein L22Cytoplasmother26.857.20E-03ENSG00000257927MRPS36P5mitochondrial ribosomal protein S36 pseudogene 5Otherother−15.279.86E-02ENSG00000135972MRPS9mitochondrial ribosomal protein S9Cytoplasmother26.507.91E-03ENSG00000120149MSX2msh homeobox 2Nucleustranscription regulator25.988.69E-03ENSG00000227035MTATP6P18Otherother27.585.67E-03ENSG00000237055MTCO1P48Otherother27.805.54E-03ENSG00000236211MTCO1P7Otherother19.325.83E-02ENSG00000233888MTCO2P17Otherother19.324.66E-02ENSG00000231576MTCO2P20Otherother−26.367.91E-03ENSG00000254118MTCYBP20Otherother−26.197.91E-03ENSG00000263241MTCYBP33Otherother−28.805.52E-03ENSG00000271687MTND5P10mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5 pseudogene 10Otherother−26.367.91E-03ENSG00000256045MTRNR2L10MT-RNR2-like 10Otherother−23.865.67E-03ENSG00000177034MTX3metaxin 3Otherother−30.004.30E-03ENSG00000169876MUC17mucin 17, cell surface associatedPlasma Membraneother−27.925.54E-03ENSG00000111046MYF6myogenic factor 6Nucleustranscription regulator−25.631.10E-02ENSG00000187616MYMKmyomaker, myoblast fusion factorPlasma Membraneother−26.367.91E-03ENSG00000225619MYT1L-AS1MYT1L antisense RNA 1Otherother−29.474.39E-03ENSG00000204272NBDYnegative regulator of P-body associationOtherother26.138.21E-03ENSG00000124479NDPNDP, norrin cystine knot growth factorExtracellular Spacegrowth factor−29.854.30E-03ENSG00000166507NDST2N-deacetylase and N-sulfotransferase 2Cytoplasmenzyme−29.944.30E-03ENSG00000242943NKAIN1P1sodium/potassium transporting ATPase interacting 1 pseudogene 1Otherother26.837.14E-03ENSG00000248745NMNAT1P4NMNAT1 pseudogene 4Otherother−29.594.34E-03ENSG00000171596NMUR1neuromedin U receptor 1Plasma MembraneG-protein coupled receptor−17.203.35E-02ENSG00000086991NOX4NADPH oxidase 4Cytoplasmenzymeimipramine blue−28.005.54E-03ENSG00000112333NR2E1nuclear receptor subfamily 2 group E member 1Nucleusligand-dependent nuclear receptor−29.844.30E-03ENSG00000225964NRIROtherother−15.044.30E-03ENSG00000101188NTSR1neurotensin receptor 1Plasma MembraneG-protein coupled receptorcontulakin-G−22.995.52E-03ENSG00000152463OLAHoleoyl-ACP hydrolaseCytoplasmenzyme27.585.67E-03ENSG00000125510OPRL1opioid related nociceptin receptor 1Plasma MembraneG-protein coupled receptorZP120, buprenorphine/naloxone, cebranopadol, buprenorphine27.835.54E-03ENSG00000171199OPRPNopiorphin prepropeptideExtracellular Spaceother−28.555.52E-03ENSG00000180409OR10AA1Polfactory receptor family 10 subfamily AA member 1 pseudogeneOtherother26.857.20E-03ENSG00000130538DOR11H12 (includes others)olfactory receptor family 11 subfamily H member 12Plasma Membraneother26.507.91E-03ENSG00000257115DOR11H12 (includes others)olfactory receptor family 11 subfamily H member 12Plasma Membraneother26.507.91E-03ENSG00000203581OR1F2Polfactory receptor family 1 subfamily F member 2 pseudogeneOtherother27.236.68E-03ENSG00000239967OR2A41Polfactory receptor family 2 subfamily A member 41 pseudogeneOtherother−27.426.04E-03ENSG00000141194OR4D1olfactory receptor family 4 subfamily D member 1Plasma MembraneG-protein coupled receptor27.485.96E-03ENSG00000254430OR6M3Polfactory receptor family 6 subfamily M member 3 pseudogeneOtherother−26.197.91E-03ENSG00000197125OR8B8olfactory receptor family 8 subfamily B member 8Plasma MembraneG-protein coupled receptor27.995.54E-03ENSG00000229386OR8B9Polfactory receptor family 8 subfamily B member 9 pseudogeneOtherother26.477.91E-03ENSG00000186508OR9I2Polfactory receptor family 9 subfamily I member 2 pseudogeneOtherother−25.631.10E-02ENSG00000234315OSTCP5oligosaccharyltransferase complex subunit pseudogene 5Otherother30.004.30E-03ENSG00000204237OXLD1oxidoreductase like domain containing 1Cytoplasmother26.138.21E-03ENSG00000225638PABPC1P12poly(A) binding protein cytoplasmic 1 pseudogene 12Otherother−28.295.52E-03ENSG00000158006PAFAH2platelet activating factor acetylhydrolase 2Cytoplasmenzyme−28.545.52E-03ENSG00000116183PAPPA2pappalysin 2Extracellular Spacepeptidase−27.925.54E-03ENSG00000135903PAX3paired box 3Nucleustranscription regulator27.725.54E-03ENSG00000112852PCDHB2protocadherin beta 2Plasma Membraneother27.885.54E-03ENSG00000254544PCNAP4proliferating cell nuclear antigen pseudogene 4Otherother−17.152.07E-02ENSG00000244302PEX5L-AS2PEX5L antisense RNA 2Otherother−27.306.04E-03ENSG00000233328PFN1P1profilin 1 pseudogene 1Otherother−26.197.91E-03ENSG00000124102PI3peptidase inhibitor 3Extracellular Spaceother−19.504.63E-03ENSG00000007541PIGQphosphatidylinositol glycan anchor biosynthesis class QCytoplasmenzyme−18.527.91E-02ENSG00000135549PKIBcAMP-dependent protein kinase inhibitor betaOtherother−28.775.52E-03ENSG00000170890PLA2G1Bphospholipase A2 group IBExtracellular Spaceenzymeniflumic acid−29.774.30E-03ENSG00000104356POP1POP1 homolog, ribonuclease P/MRP subunitNucleusenzyme−21.537.44E-03ENSG00000271776POU4F1POU class 4 homeobox 1Nucleustranscription regulator−25.719.87E-03ENSG00000233319PPIAP32peptidylprolyl isomerase A pseudogene 32Otherother18.014.35E-02ENSG00000068971PPP2R5Bprotein phosphatase 2 regulatory subunit B\'betaCytoplasmphosphatase26.507.91E-03ENSG00000126583PRKCGprotein kinase C gammaCytoplasmkinaseingenol mebutate−30.004.30E-03ENSG00000237943PRKCQ-AS1PRKCQ antisense RNA 1Otherother−30.004.30E-03ENSG00000255251DPRR23D1/PRR23D2proline rich 23 domain containing 1Otherother−29.924.30E-03ENSG00000255378DPRR23D1/PRR23D2proline rich 23 domain containing 1Otherother−19.237.91E-03ENSG00000080815PSEN1presenilin 1Plasma Membranepeptidasetarenflurbil−26.197.91E-03ENSG00000240065PSMB9proteasome subunit beta 9Cytoplasmpeptidasecarfilzomib, carfilzomib/dexamethasone/lenalidomide, carfilzomib/dexamethasone/rituximab, carfilzomib/dexamethasone−28.525.52E-03ENSG00000227462PSME2P6proteasome activator subunit 2 pseudogene 6Otherother−27.925.54E-03ENSG00000244694PTCHD4patched domain containing 4Otherother−26.367.91E-03ENSG00000171611PTCRApre T-cell antigen receptor alphaPlasma Membraneother26.507.91E-03ENSG00000172733PURGpurine rich element binding protein GOtherother30.004.30E-03ENSG00000155961RAB39BRAB39B, member RAS oncogene familyPlasma Membraneenzyme−26.197.91E-03ENSG00000198774RASSF9Ras association domain family member 9Cytoplasmtransporter−30.004.30E-03ENSG00000133119RFC3replication factor C subunit 3Nucleusenzyme27.585.67E-03ENSG00000168411RFWD3ring finger and WD repeat domain 3Nucleusenzyme−27.975.54E-03ENSG00000102760RGCCregulator of cell cycleCytoplasmother−29.624.37E-03ENSG00000101883RHOXF1Rhox homeobox family member 1Nucleusother28.015.54E-03ENSG00000234493RHOXF1P1Rhox homeobox family member 1 pseudogene 1Otherother−28.495.52E-03ENSG00000252490RN7SKP66Otherother27.915.54E-03ENSG00000199940RN7SKP75Otherother−27.925.54E-03ENSG00000200243RN7SKP79RNA, 7SK small nuclear pseudogene 79Otherother−28.125.54E-03ENSG00000266863RN7SL123PRNA, 7SL, cytoplasmic 123, pseudogeneOtherother−29.554.37E-03ENSG00000239279RN7SL184PRNA, 7SL, cytoplasmic 184, pseudogeneOtherother30.004.30E-03ENSG00000265740RN7SL339POtherother28.095.54E-03ENSG00000240577RN7SL445PRNA, 7SL, cytoplasmic 445, pseudogeneOtherother−28.805.52E-03ENSG00000239504RN7SL583PRNA, 7SL, cytoplasmic 583, pseudogeneOtherother26.857.20E-03ENSG00000244264RN7SL597POtherother−29.144.77E-03ENSG00000239744RN7SL63POtherother30.004.30E-03ENSG00000239319RN7SL854POtherother−29.774.30E-03ENSG00000202263RNA5SP22RNA, 5S ribosomal pseudogene 22Otherother−26.197.91E-03ENSG00000202225RNA5SP240RNA, 5S ribosomal pseudogene 240Otherother−27.925.54E-03ENSG00000199354RNA5SP273RNA, 5S ribosomal pseudogene 273Otherother26.837.14E-03ENSG00000104889RNASEH2Aribonuclease H2 subunit ANucleusenzyme−26.367.91E-03ENSG00000250896RNPS1P1RNA binding protein with serine rich domain 1 pseudogene 1Otherother−28.495.52E-03ENSG00000202313RNU1-64POtherother−25.481.15E-02ENSG00000252018RNU2-30PRNA, U2 small nuclear 30, pseudogeneOtherother−26.367.91E-03ENSG00000253081RNU4ATAC17PRNA, U4atac small nuclear 17, pseudogeneOtherother−28.555.52E-03ENSG00000206931RNU6-1042PRNA, U6 small nuclear 1042, pseudogeneOtherother−27.925.54E-03ENSG00000201165RNU6-1229PRNA, U6 small nuclear 1229, pseudogeneOtherother−28.035.54E-03ENSG00000207312RNU6-429PRNA, U6 small nuclear 429, pseudogeneOtherother30.004.30E-03ENSG00000206983RNU6-49PRNA, U6 small nuclear 49, pseudogeneOtherother−25.481.15E-02ENSG00000252860RNU6-570PRNA, U6 small nuclear 570, pseudogeneOtherother−27.425.67E-03ENSG00000222972RNU6-651POtherother−27.027.01E-03ENSG00000207333RNU6-680POtherother26.507.91E-03ENSG00000207058RNU6-784POtherother−28.495.52E-03ENSG00000206960RNU6-793PRNA, U6 small nuclear 793, pseudogeneOtherother28.505.52E-03ENSG00000238788RNU7-182PRNA, U7 small nuclear 182 pseudogeneOtherother−26.197.91E-03ENSG00000104237RP1RP1, axonemal microtubule associatedCytoplasmother−27.925.54E-03ENSG00000230853RPL10P11ribosomal protein L10 pseudogene 11Otherother26.477.91E-03ENSG00000240370RPL13P5ribosomal protein L13 pseudogene 5Otherother−29.924.30E-03ENSG00000230559RPL17P12ribosomal protein L17 pseudogene 12Otherother−26.967.09E-03ENSG00000243964RPL23AP65ribosomal protein L23a pseudogene 65Otherother30.004.30E-03ENSG00000230364RPL4P3ribosomal protein L4 pseudogene 3Otherother28.235.54E-03ENSG00000243914RPL5P14ribosomal protein L5 pseudogene 14Otherother−28.295.52E-03ENSG00000243521RPL5P33ribosomal protein L5 pseudogene 33Otherother−28.175.54E-03ENSG00000234415RPL5P7ribosomal protein L5 pseudogene 7Otherother−26.197.91E-03ENSG00000243742RPLP0P2ribosomal protein lateral stalk subunit P0 pseudogene 2Otherother−27.925.54E-03ENSG00000163684RPP14ribonuclease P/MRP subunit p14Nucleusenzyme26.138.21E-03ENSG00000180172RPS12P23ribosomal protein S12 pseudogene 23Otherother−27.306.04E-03ENSG00000236862RPS20P24ribosomal protein S20 pseudogene 24Otherother−29.504.37E-03ENSG00000231241RPS3AP3ribosomal protein S3A pseudogene 3Otherother26.477.91E-03ENSG00000226525RPS7P10ribosomal protein S7 pseudogene 10Cytoplasmother29.994.30E-03ENSG00000228820RPSAP1ribosomal protein SA pseudogene 1Otherother−26.967.09E-03ENSG00000227721RPSAP64ribosomal protein SA pseudogene 64Otherother26.837.14E-03ENSG00000235598RRM2P4ribonucleotide reductase M2 polypeptide pseudogene 4Otherother30.004.30E-03ENSG00000166562SEC11CSEC11 homolog C, signal peptidase complex subunitCytoplasmpeptidase−28.505.52E-03ENSG00000138623SEMA7Asemaphorin 7A (John Milton Hagen blood group)Plasma Membranetransmembrane receptor−30.004.30E-03ENSG00000240489SETP14SET pseudogene 14Otherother−26.197.91E-03ENSG00000090402SIsucrase-isomaltaseCytoplasmenzyme27.735.66E-03ENSG00000225774SIRPAP1signal regulatory protein alpha pseudogene 1Otherother26.477.91E-03ENSG00000179520SLC17A8solute carrier family 17 member 8Plasma Membranetransporter−26.697.65E-03ENSG00000105143SLC1A6solute carrier family 1 member 6Plasma Membranetransporterriluzole−27.027.01E-03ENSG00000183048SLC25A10solute carrier family 25 member 10Cytoplasmtransporter−18.953.62E-02ENSG00000225347SLC25A5P8solute carrier family 25 member 5 pseudogene 8Otherother−27.925.54E-03ENSG00000251078SLC25A5P9solute carrier family 25 member 5 pseudogene 9Otherother30.004.30E-03ENSG00000124786SLC35B3solute carrier family 35 member B3Cytoplasmtransporter−27.027.01E-03ENSG00000188338SLC38A3solute carrier family 38 member 3Plasma Membranetransporter−27.715.66E-03ENSG00000148482SLC39A12solute carrier family 39 member 12Plasma Membranetransporter−28.075.54E-03ENSG00000214329SLC9B1P2solute carrier family 9 member B1 pseudogene 2Otherother−26.197.91E-03ENSG00000185985SLITRK2SLIT and NTRK like family member 2Plasma Membraneother28.145.52E-03ENSG00000200354SNORA71Dsmall nucleolar RNA, H/ACA box 71DOtherother26.507.91E-03ENSG00000201634SNORD115-48small nucleolar RNA, C/D box 115-48Otherother26.507.91E-03ENSG00000239043SNORD127small nucleolar RNA, C/D box 127Otherother27.585.67E-03ENSG00000201330SNORD32Bsmall nucleolar RNA, C/D box 32BOtherother28.725.52E-03ENSG00000207215SNORD3Hsmall nucleolar RNA, C/D box 3HOtherother−28.495.52E-03ENSG00000225642SNRPEP5small nuclear ribonucleoprotein polypeptide E pseudogene 5Otherother−27.027.01E-03ENSG00000228741SPATA13spermatogenesis associated 13Plasma Membraneother27.585.67E-03ENSG00000258916SPATA31E2PSPATA31 subfamily E member 2, pseudogeneOtherother27.585.67E-03ENSG00000274279SPATA31E3PSPATA31 subfamily E member 3, pseudogeneOtherother27.057.01E-03ENSG00000164299SPZ1spermatogenic leucine zipper 1Nucleustranscription regulator−23.059.68E-03ENSG00000138378STAT4signal transducer and activator of transcription 4Nucleustranscription regulator30.004.30E-03ENSG00000165730STOX1storkhead box 1Cytoplasmother29.884.30E-03ENSG00000164744SUN3Sad1 and UNC84 domain containing 3Nucleusother29.354.45E-03ENSG00000217442SYCE3synaptonemal complex central element protein 3Nucleusother27.016.99E-03ENSG00000127362TAS2R3taste 2 receptor member 3Plasma MembraneG-protein coupled receptor−28.495.52E-03ENSG00000273513DTBC1D3 (includes others)TBC1 domain family member 3Extracellular Spaceother20.619.19E-02ENSG00000274611DTBC1D3 (includes others)TBC1 domain family member 3Extracellular Spaceother−25.631.10E-02ENSG00000236567TCF3P1transcription factor 3 pseudogene 1Otherother−26.697.65E-03ENSG00000167014TERB2telomere repeat binding bouquet formation protein 2Nucleusother−26.197.91E-03ENSG00000135426TESPA1thymocyte expressed, positive selection associated 1Cytoplasmother26.857.20E-03ENSG00000237675TEX36-AS1TEX36 antisense RNA 1Otherother20.648.58E-02ENSG00000226674TEX41testis expressed 41 (non-protein coding)Otherother27.585.67E-03ENSG00000008197TFAP2Dtranscription factor AP-2 deltaNucleustranscription regulator−26.197.91E-03ENSG00000243926TIPARP-AS1TIPARP antisense RNA 1Otherother−26.197.91E-03ENSG00000151952TMEM132Dtransmembrane protein 132DOtherother27.725.66E-03ENSG00000178821TMEM52transmembrane protein 52Otherother−28.875.42E-03ENSG00000154646TMPRSS15transmembrane protease, serine 15Extracellular Spacepeptidase−26.367.91E-03ENSG00000176040TMPRSS7transmembrane protease, serine 7Plasma Membranepeptidase−30.004.30E-03ENSG00000235211TMSB10P2thymosin beta 10 pseudogene 2Otherother−28.075.54E-03ENSG00000188765TMSB4XP2thymosin beta 4, X-linked pseudogene 2Otherother−30.004.30E-03ENSG00000223551TMSB4XP4thymosin beta 4, X-linked pseudogene 4Otherother−27.066.99E-03ENSG00000248697TOX4P1TOX high mobility group box family member 4 pseudogene 1Otherother25.988.69E-03ENSG00000139287TPH2tryptophan hydroxylase 2Plasma Membraneenzyme−29.514.30E-03ENSG00000234782TPT1P9tumor protein, translationally-controlled 1 pseudogene 9Otherother26.507.91E-03ENSG00000211831TRAJ61T cell receptor alpha joining 61 (non-functional)Otherother26.138.21E-03ENSG00000211880TRAJ9T cell receptor alpha joining 9Otherother27.057.01E-03ENSG00000211818TRAV39T cell receptor alpha variable 39Otherother−27.426.04E-03ENSG00000211710TRBV4-1T cell receptor beta variable 4-1Otherother−30.004.30E-03ENSG00000227550TRBV7-5T cell receptor beta variable 7--5 (pseudogene)Otherother−29.704.30E-03ENSG00000132109TRIM21tripartite motif containing 21Nucleusenzyme28.155.54E-03ENSG00000174173TRMT10CtRNA methyltransferase 10C, mitochondrial RNase P subunitCytoplasmenzyme−28.805.52E-03ENSG00000134198TSPAN2tetraspanin 2Extracellular Spaceother−28.545.52E-03ENSG00000197763TXNRD3thioredoxin reductase 3Cytoplasmenzyme−26.697.65E-03ENSG00000215218UBE2QL1ubiquitin conjugating enzyme E2 Q family like 1Nucleusenzyme28.195.52E-03ENSG00000229667UBE2V1P9ubiquitin conjugating enzyme E2 V1 pseudogene 9Otherother−30.004.30E-03ENSG00000165623UCMAupper zone of growth plate and cartilage matrix associatedExtracellular Spaceother−28.075.54E-03ENSG00000260722VN1R67Pvomeronasal 1 receptor 67 pseudogeneOtherother−26.727.88E-03ENSG00000251900VTRNA2-2POtherother27.366.18E-03ENSG00000229932YWHAZP3tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta pseudogene 3Otherother−28.075.54E-03ENSG00000155329ZCCHC10zinc finger CCHC-type containing 10Otherother27.865.54E-03ENSG00000155256ZFYVE27zinc finger FYVE-type containing 27Plasma Membraneother28.235.52E-03ENSG00000170631ZNF16zinc finger protein 16Nucleusother28.235.54E-03ENSG00000204789ZNF204Pzinc finger protein 204, pseudogeneOtherother−26.197.91E-03ENSG00000185947ZNF267zinc finger protein 267Nucleusother−27.925.54E-03ENSG00000186026ZNF284zinc finger protein 284Otherother26.837.14E-03ENSG00000180855ZNF443zinc finger protein 443Nucleustranscription regulator25.988.69E-03ENSG00000188868ZNF563zinc finger protein 563Nucleusother−30.004.30E-03ENSG00000198182ZNF607zinc finger protein 607Nucleusother−28.805.52E-03ENSG00000018607ZNF806zinc finger protein 806Otherother−28.075.54E-03ENSG00000197933ZNF823zinc finger protein 823Nucleusother+A3:I459

The data in [Table 2](#tbl2){ref-type="table"} contains all the loci which did not map to a gene but were identified as significantly altered in the breast tumor by consumption of walnut using the same calculations as for the data in [Table 1](#tbl1){ref-type="table"}. The meaning of changes in these loci has not been identified.Table 2All unmapped loci. ^©^ 2000--2018 QIAGEN. All rights reserved.Table 2Expr log ratioExpr false discovery rate (q-value)ID−304.30E-03ENSG00000206856−304.30E-03ENSG00000222133−309.14E-04ENSG00000248511304.30E-03ENSG00000249023−304.30E-03ENSG00000249239−304.30E-03ENSG00000249411304.30E-03ENSG00000249842304.30E-03ENSG00000250516−304.30E-03ENSG00000250908304.30E-03ENSG00000251066−304.30E-03ENSG00000254558−304.30E-03ENSG00000256306−304.30E-03ENSG00000259057304.30E-03ENSG00000260066304.30E-03ENSG00000264486−304.30E-03ENSG00000265621304.30E-03ENSG00000269524304.30E-03ENSG00000272108−304.30E-03ENSG00000277269304.30E-03ENSG00000279162304.30E-03ENSG00000279349−304.30E-03ENSG00000279957304.30E-03ENSG00000280068−304.30E-03ENSG00000281116304.30E-03ENSG00000254348−304.30E-03ENSG00000278777−29.9994.30E-03ENSG00000251244−29.9884.30E-03ENSG00000274918−29.9734.30E-03ENSG00000273920−29.9474.30E-03ENSG00000255305−29.8964.30E-03ENSG00000261334−29.8784.30E-03ENSG00000254242−29.864.30E-03ENSG00000278126−29.8184.30E-03ENSG00000232306−29.8014.30E-03ENSG0000027162729.7324.30E-03ENSG00000221210−29.7184.30E-03ENSG00000249818−29.6344.45E-03ENSG00000220349−29.584.37E-03ENSG0000026031729.5474.30E-03ENSG00000249189−29.4954.37E-03ENSG00000257654−29.4954.37E-03ENSG0000027522829.4954.37E-03ENSG00000228935−29.4744.32E-03ENSG00000263713−29.4654.37E-03ENSG00000257863−29.4374.45E-03ENSG00000232328−29.4244.45E-03ENSG0000025144829.44.37E-03ENSG0000027759829.3544.45E-03ENSG00000261835−29.3474.45E-03ENSG00000272940−29.2874.62E-03ENSG0000026728629.2394.62E-03ENSG0000022843829.1724.70E-03ENSG00000223738−29.1434.77E-03ENSG00000231916−29.1434.77E-03ENSG0000023370329.1344.77E-03ENSG0000027819229.0684.71E-03ENSG00000264642−28.8435.52E-03ENSG0000023288728.8415.08E-03ENSG00000249061−28.8025.52E-03ENSG00000229370−28.8025.52E-03ENSG00000233372−28.8025.52E-03ENSG00000235147−28.8025.52E-03ENSG0000025831428.6795.52E-03ENSG0000027444428.5665.52E-03ENSG00000264526−28.5485.52E-03ENSG00000256293−28.5395.52E-03ENSG00000229242−28.5395.52E-03ENSG00000240103−28.5395.52E-03ENSG00000257129−28.5395.52E-03ENSG00000269514−28.5185.52E-03ENSG00000276538−28.5175.52E-03ENSG00000281411−28.4925.52E-03ENSG00000232140−28.4925.52E-03ENSG00000234941−28.4925.52E-03ENSG00000237903−28.4925.52E-03ENSG00000248656−28.4925.52E-03ENSG00000260093−28.4925.52E-03ENSG00000274370−28.3115.52E-03ENSG00000273816−28.295.52E-03ENSG0000028111428.235.54E-03ENSG0000020226928.235.54E-03ENSG0000023202828.235.54E-03ENSG0000023928828.235.54E-03ENSG0000026167928.235.54E-03ENSG0000027086628.1885.52E-03ENSG0000023212028.1885.52E-03ENSG0000023468328.1885.52E-03ENSG0000028295028.1545.54E-03ENSG0000025585128.1545.54E-03ENSG0000028104628.1445.52E-03ENSG0000025084728.1445.52E-03ENSG0000026168028.0945.54E-03ENSG00000233616−28.0835.52E-03ENSG0000027892328.0775.54E-03ENSG00000244167−28.0685.54E-03ENSG00000249102−28.0685.54E-03ENSG00000263717−28.0685.54E-03ENSG0000026418228.0065.54E-03ENSG0000025166827.9855.54E-03ENSG0000025602927.9855.54E-03ENSG00000280164−27.9715.54E-03ENSG00000249631−27.9245.54E-03ENSG00000225148−27.9245.54E-03ENSG00000255572−27.9245.54E-03ENSG00000260329−27.9245.54E-03ENSG00000270889−27.9245.54E-03ENSG0000027268527.9145.54E-03ENSG0000027912727.8625.54E-03ENSG00000283057−27.8295.54E-03ENSG00000271568−27.7795.54E-03ENSG00000254502−27.7795.54E-03ENSG00000263985−27.7475.54E-03ENSG0000025429027.7335.66E-03ENSG0000022713327.7335.66E-03ENSG0000024383127.7335.66E-03ENSG0000025992427.7335.66E-03ENSG0000027325927.7335.66E-03ENSG0000027970827.7225.66E-03ENSG0000024196127.7195.54E-03ENSG00000258205−27.715.66E-03ENSG0000026067427.6445.67E-03ENSG0000025479227.6445.67E-03ENSG0000022572027.5795.67E-03ENSG0000026026127.5795.67E-03ENSG0000026581927.5795.67E-03ENSG0000027251227.5795.67E-03ENSG0000027948527.5795.67E-03ENSG0000028002327.5795.67E-03ENSG00000280188−27.4965.66E-03ENSG0000019928527.4775.67E-03ENSG0000023800927.4775.67E-03ENSG0000024116827.4775.67E-03ENSG0000025827127.4775.67E-03ENSG0000025945027.4775.67E-03ENSG00000261379−27.4246.04E-03ENSG0000028217327.4076.04E-03ENSG0000020153527.3576.18E-03ENSG00000278269−27.3236.26E-03ENSG00000263938−27.0586.99E-03ENSG00000269981−27.0586.99E-03ENSG0000027481527.0517.01E-03ENSG00000279122−27.0227.01E-03ENSG00000217512−27.0227.01E-03ENSG00000221376−27.0227.01E-03ENSG00000264855−27.0227.01E-03ENSG00000269974−27.0227.01E-03ENSG00000271118−27.0187.01E-03ENSG00000224661−27.0187.01E-03ENSG00000233645−27.0187.01E-03ENSG00000234622−27.0187.01E-03ENSG00000244259−27.0187.01E-03ENSG00000264715−27.0187.01E-03ENSG00000265445−27.0187.01E-03ENSG00000267004−27.0187.01E-03ENSG00000271253−27.0187.01E-03ENSG0000027595827.0056.99E-03ENSG0000022559127.0056.99E-03ENSG00000229791−26.967.09E-03ENSG00000207027−26.967.09E-03ENSG00000229878−26.967.09E-03ENSG00000233778−26.967.09E-03ENSG00000261620−26.967.09E-03ENSG00000264222−26.917.01E-03ENSG0000025678326.8547.20E-03ENSG0000027793026.8547.20E-03ENSG0000027917326.8267.14E-03ENSG0000020137026.8267.14E-03ENSG0000020241026.8267.14E-03ENSG0000022490426.8267.14E-03ENSG0000024015926.7617.20E-03ENSG0000023068726.7617.20E-03ENSG0000025877326.7617.20E-03ENSG00000260702−26.6887.65E-03ENSG00000224945−26.6887.65E-03ENSG00000226986−26.6887.65E-03ENSG00000271993−26.6887.65E-03ENSG00000280395−26.6887.65E-03ENSG0000028130426.4987.91E-03ENSG0000023620926.4987.91E-03ENSG0000023755526.4697.91E-03ENSG0000021318426.4697.91E-03ENSG0000023129726.4697.91E-03ENSG0000023342826.4697.91E-03ENSG0000025381626.4697.91E-03ENSG0000026208926.4697.91E-03ENSG0000026728426.4697.91E-03ENSG0000027310026.4697.91E-03ENSG0000027496426.4697.91E-03ENSG0000027716926.4697.91E-03ENSG0000027787526.4697.91E-03ENSG0000027953726.4697.91E-03ENSG00000280198−26.3627.91E-03ENSG00000199901−26.3627.91E-03ENSG00000206672−26.3627.91E-03ENSG00000206806−26.3627.91E-03ENSG00000213279−26.3627.91E-03ENSG00000254367−26.3627.91E-03ENSG00000259275−26.3627.91E-03ENSG00000262766−26.3627.91E-03ENSG00000265359−26.3627.91E-03ENSG00000267717−26.3627.91E-03ENSG00000269014−26.3627.91E-03ENSG00000271897−26.3627.91E-03ENSG00000271917−26.3627.91E-03ENSG00000277026−26.3627.91E-03ENSG00000279269−26.3627.91E-03ENSG00000279910−26.3627.91E-03ENSG00000280114−26.3627.91E-03ENSG00000280711−26.2997.91E-03ENSG00000236116−26.1927.91E-03ENSG00000204556−26.1927.91E-03ENSG00000207229−26.1927.91E-03ENSG00000221326−26.1927.91E-03ENSG00000227740−26.1927.91E-03ENSG00000228176−26.1927.91E-03ENSG00000228543−26.1927.91E-03ENSG00000233516−26.1927.91E-03ENSG00000233887−26.1927.91E-03ENSG00000235358−26.1927.91E-03ENSG00000248490−26.1927.91E-03ENSG00000249284−26.1927.91E-03ENSG00000254330−26.1927.91E-03ENSG00000254836−26.1927.91E-03ENSG00000255344−26.1927.91E-03ENSG00000260603−26.1927.91E-03ENSG00000261618−26.1927.91E-03ENSG00000265554−26.1927.91E-03ENSG00000268597−26.1927.91E-03ENSG00000271643−26.1927.91E-03ENSG00000274421−26.1927.91E-03ENSG00000276073−26.1927.91E-03ENSG00000278909−26.1927.91E-03ENSG00000280061−26.1927.91E-03ENSG0000028126226.1328.21E-03ENSG0000021712026.1328.21E-03ENSG0000023170526.1328.21E-03ENSG0000024377926.1328.21E-03ENSG0000027136426.1328.21E-03ENSG00000276507−25.9988.63E-03ENSG0000026598525.9838.69E-03ENSG0000022367225.9838.69E-03ENSG0000022519325.9838.69E-03ENSG0000025443625.9838.69E-03ENSG0000025649425.9838.69E-03ENSG0000026169625.9838.69E-03ENSG0000026360625.9838.69E-03ENSG0000026702725.9838.69E-03ENSG0000027334825.9838.69E-03ENSG00000280245−25.719.87E-03ENSG00000220076−25.719.87E-03ENSG00000253960−25.719.87E-03ENSG00000260244−25.719.87E-03ENSG0000027907725.6879.93E-03ENSG0000019963525.6879.93E-03ENSG00000276337−25.6331.10E-02ENSG00000228035−25.6331.10E-02ENSG00000239036−25.6331.10E-02ENSG00000263489−25.4841.15E-02ENSG00000242953−25.4841.15E-02ENSG00000255774−22.9561.33E-02ENSG0000027452222.7923.30E-02ENSG0000027001922.3833.50E-02ENSG0000027246122.2661.01E-02ENSG00000278233−21.3527.91E-03ENSG00000239381−20.7118.68E-02ENSG0000027666820.559.19E-02ENSG0000027882419.8157.91E-03ENSG00000243429−19.6427.91E-03ENSG00000272366−19.6322.85E-02ENSG00000255740−19.4915.52E-03ENSG0000022777718.8244.75E-02ENSG00000272763−18.0336.99E-03ENSG0000027518817.9848.53E-02ENSG00000256757−17.9831.03E-02ENSG00000255871−16.8195.84E-02ENSG00000265129−16.5759.30E-04ENSG0000023387516.4575.88E-03ENSG00000237158−16.0354.59E-02ENSG00000268906−15.5015.14E-02ENSG00000201892−2.4143.36E-02ENSG00000277089

IPA analyses use the results shown in [Table 1](#tbl1){ref-type="table"} to organize the genes into functional networks. This is important to identify the net effect of multiple changes on gene expression. The data in [Table 3](#tbl3){ref-type="table"} lists all 25 significantly modified gene networks that were identified by IPA analyses, the genes in those networks and the top diseases and functions associated with the genes. The network 'score', the negative log of the overall statistical significance of the network, is shown. A network score of 41 means that in 10^−41^ experiments of a similar type one might to encounter this pattern of mRNA expression changes by chance. The data in this table indicates the effect of walnut consumption on gene networks in the existing breast cancer and could indicate other diseases or functions in which dietary walnut may have benefit. Focused research would be needed to ascertain this benefit.Table 3All gene networks identified by IPA analyses and the molecules in that network. © 2000--2018 QIAGEN. All rights reserved.Table 3IDMolecules in NetworkScoreFocus MoleculesTop Diseases and Functions1ADGRG4,AJAP1,AVPR1B,BDKRB1,CD3,CDH9,DAB1,DDX4,DPYSL5,ECH1,ERK,estrogen receptor,FAM49A,Gpcr,Histone h3,HOXB5,Insulin,Jnk,MRPS9,NMUR1,NTSR1,OPRL1,P38 MAPK,PAPPA2,PI3K (complex),Pkc(s),PLC,POU4F1,PSEN1,SI,SLC38A3,TCR,TFAP2D,TSPAN2,ZCCHC104123Reproductive System Development and Function, Carbohydrate Metabolism, Lipid Metabolism3ADCY,Akt,AMPK,BMP2,CCL14,CDH18,Cg,CHRM2,Collagen(s),Creb,DEFA6,GFRA4,Growth hormone,GZMA,HTR7,KCNJ3,Mapk,MAPK4,mir-15,NDP,NOX4,NR2E1,PDGF BB,Pka,PPP2R5B,Proinsulin,Ras,SEMA7A,Serine Protease,SLC39A12,TMPRSS7,TMPRSS15,Tnf (family),trypsin, Vegf3219Embryonic Development, Nervous System Development and Function, Organ Development4C1q,CD1A,CLEC4A,CLEC4M,CR2,CSN2,CYP46A1,ERK1/2,FCRLA,GFRA2,IAPP,IFI44,IFN alpha/beta,IFN Beta,Ifnar,IgG,IgG1,IgG2a,IgG2b,Igm,IL1,IL23,IL12 (complex),IL23R,Immunoglobulin,Interferon alpha,LDL,PI3,Pro-inflammatory Cytokine,PSMB9,RNASEH2A,SPZ1,STAT4,Tgf beta,TRIM212717Endocrine System Disorders, Gastrointestinal Disease, Immunological Disease5ADAT1,AGPAT1,ARHGEF4,CCDC134,CD200,CELF5,ELAVL2,GAD,H2AFB3 (includes others),HIST1H2BO,IFI44,IFNG,IGFN1,IL5,IL6,KLK8,LCP2,LECT2,MAPK8,MDGA2,MOV10,MRPL22,NRTN,OSBP2,PAIP2B,PI3,PIGQ,PKIB,RP1,SIRPB1,SLC35B3,SUN3,TESPA1,TNFSF13B,ZNF4432516Cell-To-Cell Signaling and Interaction, Cellular Growth and Proliferation, Hematological System Development and Function6ACTA2,Actn3,AUH,C11orf86,C3orf38,C3orf79,CHST12,COL27A1,FN1,HEATR5B,IL4,KLHL1,MARCKS,Mcpt4,MUC17,Mucin,NDST2,OPRPN,OXLD1,PI3,PPARD,PSMG1,RAB10,RAB33B,RAB39B,RGCC,SEC11C,SLC1A6,SPEF2,SPG11,STK32C,STOX1,SYT2,TRAPPC6B,ZFYVE272315Cell-To-Cell Signaling and Interaction, Carbohydrate Metabolism, Drug Metabolism7APP,BNIP1,C18orf21,CALML3,CBFA2T2,CCDC140,CLEC12A,DTD1,FOLR1,GOSR2,GTF2E1,HIST1H2BM,KCNIP4,KCNIP4-IT1,KCNN3,MESDC2,NEPRO,PCBD2,POP1,POP4,POP5,POP7,PURG,RAD51C,RHOXF1,RPP14,RPP21,RPP25,RPP30,RPP40,RSPH10B/RSPH10B2,SURF2,TBC1D10C,TERB2,VTN2114RNA Post-Transcriptional Modification, Cell-To-Cell Signaling and Interaction, Skeletal and Muscular System Development and Function8ABHD10,ABRAXAS1,ABRAXAS2,Adaptor protein 2,ADCYAP1,ANKRD40,ATP2C1,BDNF,BRCA1,BUD13,CCBE1,CCNI,CHSY1,CT45A10/CT45A5,DUSP27,ELAVL1,FAM46C,FLYWCH1,GOLT1B,HCN1,HCN3,HOXC12,LMBRD1,MLEC,MYADM,NABP1,NABP2,PPTC7,RPRM,SDCBP,SELENOT,SLC17A8,TBC1D3 (includes others),USP7,YPEL51913Amino Acid Metabolism, Molecular Transport, Small Molecule Biochemistry9ABT1,ANKRD30BP2,CCDC153,CNBP,COX10,CST5,EMP3,ESPNL,FKTN,FOLH1,GAR1,HGD,MED11,MED18,MED30,MED12L,MED13L,NAV3,NDUFB7,NIP7,NOP53,NR3C1,OLAH,PAK1,PARP4,PPARG,PPIC,PPP1R14C,SMARCA4,SPEN,SURF6,TRAP/Media,Wap,ZNF16,ZNF8231913Cellular Assembly and Organization, Cellular Compromise, Gastrointestinal Disease10AK7,AQP3,AQP12A/AQP12B,ARNT2,BLOC1S3,BLOC1S4,BLOC1S5,BMPER,CCDC134,CDH3,COL12A1,COMP,DAND5,ESR2,GALNT4,GGCT,KCMF1,MAPK4,MTX3,NR5A2,PAFAH2,POLD4,RASSF7,RASSF9,RBP3,SAPCD2,SNRK,SOX2,SOX13,sPla2,TNF,TXNRD3,XPO1,ZFP36L2,ZNF2671712Cancer, Organismal Injury and Abnormalities, Reproductive System Disease11ANXA3,AR,ATP13A4,BOK,CFAP206,CLDN3,CUL2,CYLC2,DDT,EDN2,ERBIN,GGCT,GUCY1A3,HLA-DQB2,KRT40,KTI12,LRRC1,MARCH4,Marcks,MIIP,MLKL,NUDT1,PDIA5,PFKFB2,PPP1CA,PRL,PTCHD4,SCN4A,SNW1,SYCE3,TMEM132D,TNFRSF10A,TP53,UCMA,ZNF5631712Organ Morphology, Reproductive System Development and Function, Tissue Morphology12ADAM9,ADAM29,ADAM30,ADAMTS2,ADAMTS7,AHCTF1,CEACAM,CST4,CTNNB1,DACT2,DBH,DHDH,EGFR,FERD3L,FZD9,GRID1,IGLL1/IGLL5,IL2RA,IQGAP2,JADE1,LFNG,MDFI,Metalloprotease,MFNG,MYF5,PAPPA2,PTCRA,RAB18,SLC25A10,SPATA13,STX2,TCF3,TRMT10C,TSC22D1,ZNF6071511Cell-mediated Immune Response, Lymphoid Tissue Structure and Development, Hematopoiesis13ACP5,ALPL,ARG1,CCNC,CXorf21,ELOA,EXOSC8,GADD45B,GTF2A1,GTF2A2,GTF2E2,GTF2F1,GTF2F2,GTF2H1,GTF2H3,HAS2,HMGN1,MED13,MSX2,MTPN,PCDHB2,POLR2G,POLR2J2/POLR2J3,RNA pol2-transcription factor,RNA polymerase II,S100A6,SBDS,SNAI2,SPP1,TCEA1,TCEA2,TFIIA,TFIIE,TFIIF,UBE2QL155Gene Expression, Dental Disease, Digestive System Development and Function14FAM90A1,FAM90A26 (includes others)21Cancer, Neurological Disease, Organismal Injury and Abnormalities15CBLN2,miR-125b-5p (and other miRNAs w/seed CCCUGAG)21Cell Morphology, Cellular Function and Maintenance, Hematological System Development and Function16LHX2,OR8B821Cellular Development, Cellular Growth and Proliferation, Digestive System Development and Function17mir-3146,miR-3146 (miRNAs w/seed AUGCUAG)2118mir-933,miR-933 (miRNAs w/seed GUGCGCA)21Cancer, Organismal Injury and Abnormalities, Reproductive System Disease19MIR4737,miR-4737 (miRNAs w/seed UGCGAGG)2120ANKRD30BL,HR21Dermatological Diseases and Conditions, Developmental Disorder, Embryonic Development21mir-3118,miR-3118 (and other miRNAs w/seed GUGACUG)21Cell Morphology, Cell-To-Cell Signaling and Interaction, Nervous System Development and Function22T2r,TAS2R321Behavior, Cancer, Organismal Injury and Abnormalities23ZNF221,ZNF223,ZNF28421Cancer, Neurological Disease, Organismal Injury and Abnormalities24MIR6757,miR-6757-3p (miRNAs w/seed ACACUGG),miR-6757-5p (miRNAs w/seed AGGGAUG)2125NFYB,PTPRD,PTPRS,SLITRK221Cellular Growth and Proliferation, Developmental Disorder, Endocrine System Disorders

2. Experimental design, materials and methods {#sec2}
=============================================

2.1. Experimental design {#sec2.1}
------------------------

Women were recruited for this clinical trial when they came to the clinic for their first diagnostic biopsy, before it was known if the lump was cancer or not. Potential subjects must have had lumps large enough for the necessary biopsies for diagnosis and 1 or 2 extra research biopsies. After signing informed consent, subjects were randomized into walnut-consuming or control groups. Subjects in the walnut group immediately began to consume 2 ounces of walnuts per day until surgery. If a subject was later found to not have cancer or if the cancer was to be treated with chemotherapy or radiation prior to surgery, she was no longer included in the trial. Thirty-eight women were initially recruited. Twenty-four of 38 subjects were disqualified because the lump was benign, or the subject was to receive chemo- or radiation therapy prior to surgery. An additional 4 subjects were disqualified because the extracted mRNA of at least one specimen did not pass quality control. Remaining were 10 subjects; five in the walnut consuming and five in the control group. mRNA was extracted from each individual specimen then genome wide mRNA was determined in each specimen via next-generation sequencing. Gene expression ratios were calculated for each gene as: (walnut surgery/walnut biopsy)/(control surgery/control biopsy) for further analyses [@bib1].

2.2. IRB approval {#sec2.2}
-----------------

The Marshall University Office of Research Integrity has an Institutional Review Board (IRB), which reviews and monitors all human subject research conducted at Marshall University, St. Mary\'s Medical Center, Cabell Huntington Hospital and the Edwards Cancer Center. The research protocol and participant informed consent were approved by the IRB (protocol number **339384--3)**. This study was not listed at [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0030}. Potential study participants were identified from records review by the Research Study Nurse prior to their appointment for a diagnostic biopsy. At the appointment time, the potential participant was interviewed by the study nurse, the study was explained and informed consent was obtained. The physician obtained one or two additional biopsies for research use when the biopsy was obtained for pathology studies.

**Inclusion criteria:** All subjects: 1) were female and with a breast mass that, according to standard of care, was to be biopsied for diagnosis and was large enough to obtain the needed biopsies for pathology and research; 2) understood and were willing to sign the informed consent form; 3) had an ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1; (0 - Fully active, able to carry on all pre-disease performance without restriction. 1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.) 4) were between 18 and 90 years of age; 5) were recruited as available without regard to race or ethnicity.

**Exclusion criteria:** Excluded persons were: 1) those who do not like or who were allergic to walnuts or other tree nuts; 2) those with any metabolic disease that could be affected by walnut consumption; 3) those with a life expectancy less than 6 months; 4) those who were pregnant (to prevent confounding due to pregnancy hormonal factors).

2.3. Clinical protocol {#sec2.3}
----------------------

Subjects were consented at their first visit and were randomized into treated (consume walnut) or control (no added walnuts) groups. Routine clinical data were recorded (age, weight, height, family history, etc.). A five ml blood specimen in EDTA was collected for the research laboratory. After the initial biopsy, the subject was asked to continue to consume the usual diet and to not change consumption of any medication or supplements. If she was randomized to the walnut group, the subject was given 30, one ounce packages of walnuts, was asked to consume two packages (two ounces) of walnuts daily and to return remaining packages for counting. If needed, due to extended time for the clinical workup, the subject was given additional packages of walnuts to allow for continued consumption of two ounces of walnuts per day until surgery (about two to three weeks). Control group subjects were asked to not intentionally consume walnuts. At the conclusion of the study, each subject was asked to identify whether any changes were made to the usual diet especially in the areas of fruits, vegetables, nuts or supplement consumption and fats used in cooking and whether walnuts were consumed (walnut group) or not (control group).

At the time that ultrasound guided core needle biopsies of the breast mass were obtained for diagnosis, one or two extra cores were taken for research use. In the procedure room, immediately upon removal, the biopsies for research were placed in Qiagen All-Protect tissue reagent ([Qiagen.com](http://Qiagen.com){#intref0035}) to preserve RNA, DNA and protein for up to 7 days at room temperature. Biopsies were delivered to the research laboratory for initial processing within 2 hours.

If the pathology report indicated that the lump was not cancer, no further tissue was collected and the subject was no longer part of the study. If the biopsied tissue was breast cancer and surgery was scheduled without intervening radiation or chemotherapy, another specimen of tumor tissue and blood was collected at surgery. A small section of macroscopically viable tumor, away from the clean margin, was excised then immediately placed in Qiagen All-Protect tissue reagent, as before. Any patient who, according to the clinical care plan, was to receive either chemotherapy or radiation prior to surgery was no longer part of the study so as to not confound analyses.

2.4. Laboratory protocols {#sec2.4}
-------------------------

Total RNA was extracted using RNeasy, Lipid Tissue kit ([Qiagen.com](http://Qiagen.com){#intref0040}). This micro-kit is suitable for less than five mg of tissue and for extracting up to 45 μg of total mRNA. mRNA was checked for quantity and sent to the Marshall University Genomics Core Facility for further processing. The Genomics Core is a full service facility and provided RNA quality assessment, RNA-Seq analysis on each specimen, and DESeq2 expression profiling analyses of the data.

2.5. RNA sequencing: next-generation sequencing {#sec2.5}
-----------------------------------------------

RNA sample quality was assessed on RNA Pico chips in using an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). RNA samples had RNA Integrity Numbers (RIN) ranging from 2.6 to 9.4. One microgram of total RNA was used to construct RNA-Seq libraries using a TruSeq stranded total RNA library prep kit with RiboZero(H∖M∖R) ribosomal RNA reduction (Illumina Inc., San Diego, CA) according to the kit\'s instructions. RNA fragmentation times were modified based on RNA samples\' RIN value to generate inserts of equal size across all libraries.

Twenty RNA-Seq libraries were clustered on an Illumina cBot and sequenced on a HiSeq 1500 platform, in a 2 x 50 base paired end design yielding a minimum of 50 million reads per sample. Five matched pairs of samples (initial biopsy and subsequent surgery) were collected from each of the walnut consuming and control groups.

Reads were trimmed using Trimmomatic v 0.36 [@bib2] to remove low-quality base calls and adapter sequences, and then aligned to the human reference genome GRCh38 using HISAT v2.1.0 [@bib3]. Resulting bam files were sorted and indexed with SamTools v1.3.1 [@bib3], [@bib4], and PCR and optical duplicate reads marked using Picard tools v2.6.0. The numbers of reads mapping to each gene for each sample were counted using the R/Bioconductor package GenomicAlignments, v1.12.2 [@bib5] and the Ensembl gene database for GRCh38, build 84 [@bib6]. Differential gene expression was computed using DESeq2 version 1.10.0 [@bib7], with a statistical model comparing the ratio of expression between surgery and biopsy specimens for the walnut-consuming group to the ratio of expression between surgery and biopsy specimens for the control group, as described in "statistical analyses" below.

2.6. Statistical analyses {#sec2.6}
-------------------------

Differences between groups (walnut or control) in fractions of individual fatty acids as determined by gas chromatography or in clinical parameters were determined by T-test with a significance level of p ≤ 0.05.

It was expected that there would be large interpatient heterogeneity thus the baseline mRNA expression of individual genes would be highly variable between patients. The analyses of biopsy and surgical specimens allowed each patient to serve as her own control. Gene expressions for the sample collected at initial biopsy and the sample collected at surgery were determined and the ratios of these expressions were calculated for each patient. Then the means of the ratio of expressions were compared between the walnut-consuming group and the control group. The comparison was performed using DESeq2, which models the read count per gene using a negative binomial distribution, and moderates the estimated expression changes to account for the dependence on overall read count [@bib7]. Each patient was assigned a unique id within their treatment (walnut or control) group, and the statistical model (equation [(1)](#fd1){ref-type="disp-formula"}):

was passed to DESeq2, with extraction taking values "biopsy" or "surgery", and treatment taking values "walnut" or "control". Genes that were significant for the extraction**:**treatment interaction parameter at a Benjamini-Hochberg (B--H) controlled false discovery rate of 10% were considered to be differentially expressed. The corresponding moderated fold change computed by DESeq2 is an estimate of this parameter, and can thus be considered to be an estimate of the quantities:$$\frac{\ \ \ \ \ \ \frac{g_{w,s}}{g_{w,b}}}{\frac{g_{c,s}}{g_{c,b}}}$$

In Equation [(2)](#fd2){ref-type="disp-formula"}, 'g' represents the expression level of gene 'g', the subscripts 'w' and 'c' represent samples in the walnut and control groups, respectively, and the subscripts 's' and 'b' represent samples from surgery and biopsy, respectively. Thus, the ratio of expression of gene 'g' from surgical specimens verses biopsy specimens of walnut patients was divided by the ratio of expression of gene 'g' from surgical specimens verses biopsy specimens of control patients. These analyses determined whether, across the group, there were [significant]{.ul} and [consistent]{.ul} changes in the mRNA expression of specific genes due to walnut consumption and provide the input for subsequent Ingenuity Pathway analyses.

2.7. Ingenuity Pathway analyses (IPA) {#sec2.7}
-------------------------------------

The complex data resulting from RNA seq expression profiling requires complex analyses. Data were analyzed by use of IPA [@bib8]. Final downstream phenotypic effects are due to the balance of positive and negative influences on expression of genes in a pathway. The goal of the IPA Downstream Effects Analysis is to identify genes and the resulting functions that are expected to increase or decrease, given the observed gene expression changes in the experimental dataset [@bib8]. Downstream Effects Analysis is based on expected causal effects between genes and functions; the expected causal effects are derived from the literature compiled in the Ingenuity^®^ Knowledge Base [@bib8]. The analysis examines genes in the dataset that are known to affect functions, compares the genes' *direction of change* to expectations derived from the literature then issues a prediction for each function based on the direction of changes in the dataset [@bib8]. IPA uses a z-score algorithm to make predictions which is designed to reduce the chance that random data will generate significant predictions [@bib8]. A publication further describing Downstream Effects Analyses can be found at [@bib9].

The p-values for networks were calculated using a Fisher exact test with B--H multiple testing corrections. The networks were generated through the use of IPA [@bib8]. The network score is based on the hypergeometric distribution and is calculated with the right-tailed Fisher\'s Exact Test with B--H multiple testing corrections. For example, for a network with a p-value of 1 × 10^−30^, the network\'s score = \[-log(Fisher\'s Exact test result)\] = 30. Thus, a score of 30 can be interpreted as meaning that if there were no associations between walnut consumption and the gene expression changes seen in the network, an overlap between the network and the differentially expressed gene set would only occur 1 in 10^30^ times in similar experiments.

Files containing the raw reads, along with a shell script describing the complete data analysis pipeline, were deposited to the Gene Expression Omnibus (GEO) at the National Center for Biotechnology Information (NCBI) and can be obtained via accession number [GSE111073](ncbi-geo:GSE111073){#intref0045}. <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111073>.
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